NDAORALTABLET
Approved
Jan 2025
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
4/8 — Partial
SYMBRAVO (meloxicam, rizatriptan) by Axsome Therapeutics is cyclooxygenase inhibitors [moa]. First approved in 2025.
Drug data last refreshed 22m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SYMBRAVO is a fixed-dose oral tablet combining meloxicam (a cyclooxygenase inhibitor) and rizatriptan, approved January 30, 2025 by Axsome Therapeutics. This combination addresses pain management by targeting both inflammatory pathways and migraine-specific mechanisms. The product represents a novel formulation strategy for patients requiring dual anti-inflammatory and triptan therapy.
Growth18.7 years to LOE
Early-stage growth product with nascent commercial infrastructure; expect expanding team headcount as market access and physician awareness develop.
Mechanism of Action
Cyclooxygenase Inhibitors
Pharmacologic Class:
Nonsteroidal Anti-inflammatory Drug
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Axsome Therapeutics is hiring 10 roles related to this product
Worked on SYMBRAVO at Axsome Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.